RP- HPLC and TLC- densitometric methods for determination of oxfendazole in the presence of its alkali -induced degradation product

Abstract
Accurate, selective, and sensitive reversed phase high performance liquid chromatography (RP-HPLC) and thin-layer chromatography (TLC) - densitometry methods have been developed and validated for determination of oxfendazole in the presence of its alkali-induced degradation product. The developed RP-HPLC method was based on the separation of the two components using 0.05M KH₂PO₄ (adjusted to pH=5), methanol and acetonitrile (50:30:20, by volume) as a mobile phase in isocratic elution mode on BDS Hypersil C₁₈ column at a flow rate of 1mL min⁻¹ and ultraviolet (UV) detection at 225nm. The components were well resolved from each other with significantly different Rₚ values of 7.3 and 4.05min for oxfendazole and its alkali-induced degradation product, respectively. The method was applied in the range of (3-15µg mL⁻¹). On the other hand, TLC- densitometric method depends on the separation and quantitation of oxfendazole and its alkali-induced degradation product on TLC silica gel 60 F₂₅₄ plates, using chloroform-methanol and glacial acetic acid (90:8:2, by volume) as the developing system followed by densitometric measurement at 292nm. The studied components were well resolved from each other with significantly different Rₚ values of 0.75 and 0.2 for oxfendazole and its degradation product, respectively. The method was applied in the range of (0.5-6µg / spot). The developed methods were validated according to the International Conference on Harmonization (ICH) guidelines demonstrating good accuracy and precision. The results were statistically compared with those obtained by the reported method, and no significant difference was found.

Keywords: oxfendazole, oxfendazole degradation product, RP-HPLC and TLC-densitometry

Introduction
Oxfendazole chemically known as: [5-(Phenylsulfinyl)-1H-benimidazol-2-yl] carbamic acid methyl ester Figure 1. It is a benimidazole carbamate anthelmintic used in veterinary medicine. Different analytical techniques were applied for quantitative estimation of oxfendazole including potentiometric titration, radio immunoassay, spectrophotometric methods and HPLC methods even alone or in presence of other compounds. Oxfendazole is an amide group containing compound that made it highly sensitive to hydrolytic degradation in basic conditions with the production of an amide group containing compound that made it highly sensitive even alone or in presence of other compounds. The aim of this work is to develop and validate simple, sensitive and selective chromatographic methods for the determination of oxfendazole in presence of its alkali-induced degradation product (2-amino-5-Phenylsulfinyl benzimidazole) without preliminary separation. The proposed methods were found to be fast and simple and can be used for its routine analysis in quality control laboratories.

Experimental
Instruments
a. HPLC, LDC Analytical (Milton Roy, USA), equipped with Diode-array UV-visible detector and auto sampler injector, using BDS Hypersil C₁₈ column (4.6×250mm), particle size (5µm). The chromatographic analysis was carried out using (EZ Chrom Elit) data analysis program.

Figure 1 Chemical structure of oxfendazole.
Materials and reagents

Pure standard

Standard oxfendazole powder was kindly supplied by Unipharma Co. for pharmaceutical industries, Al Obour city, Cairo, Egypt. (B. NO.60414005).

Pharmaceutical preparation

Unifendazole® suspension, the product of Unipharma Co. for pharmaceutical industries, Al Obour city, Cairo, Egypt. (B.NO.390215), which labeled to contain 22.5% w/v oxfendazole.

Reagents and solvents

a. Hydrochloric acid, (El-Nasr Co., Egypt), prepared as 0.1M methanolic solution and 1M aqueous solution.
b. Sodium hydroxide, (El-Nasr Co., Egypt), prepared as 1M aqueous solution.
c. Methanol, acetonitrile and chloroform, all of HPLC grade, (Sigma-Aldrich, Germany).
d. Glacial acetic acid and O-phosphoric acid.
a. 0.05M phosphate buffer solution, prepared by dissolving 3.4gm of potassium dihydrogen phosphate (KH$_2$PO$_4$) in 500mL distilled water and the solution adjusted to (pH=5) using o- phosphoric acid.

Degraded sample

One gram of oxfendazole was dissolved in 25mL 0.1M methanolic hydrochloric acid, and then transferred into 250mL conical flask, then 50mL of 1M NaOH solution was added. The flask was heated to boiling under reflux for 1hr, cooled and neutralized with 1M HCl. Subsequently, the solution was dried under vacuum then the degradation product was extracted with methanol and re-crystallized after evaporating methanol.

Standard solutions

a. Stock standard solution of oxfendazole (1mg mL$^{-1}$) was prepared by dissolving 0.1g of oxfendazole in 10mL 0.1M methanolic hydrochloric acid and complete to 100mL with methanol.
b. Working solution of oxfendazole (100µg mL$^{-1}$):10mL of oxfendazole accurately transferred from its stock standard solution into 100mL volumetric flask, then the volume was completed to the mark with methanol.
c. Stock standard solution of oxfendazole degradation product (1mg mL$^{-1}$) was prepared by dissolving 0.1g of (2-amino-5-Phenylsulfinyl benzimidazole) in 50mL methanol and complete to 100mL with the same solvent.
d. Working solution of oxfendazole degradation product (100µg mL$^{-1}$): 10mL of oxfendazole degradation product accurately transferred from its stock standard solution into 100mL volumetric flask, then the volume was completed to the mark with methanol.

Procedures

Construction of calibration curves

RP-HPLC method: Aliquots of oxfendazole equivalent to (30-150µg), were accurately transferred from its respective working standard solution (100µg mL$^{-1}$) into a set of 10mL volumetric flasks and the volume was then completed to the mark with the mobile phase [potassium dihydrogen phosphate (pH=5): methanol: acetonitrile] (50:30:20, by volume). A 20µL aliquot of each solution was injected into a BDS Hypersil C$_2$ column (4.6×250mm), particle size (5µm), using the mobile phase, at flow rate 1.0mL min$^{-1}$ and UV detection at 225nm. Calibration curve was constructed by plotting the peak area against the corresponding concentrations of oxfendazole.

TLC-densitometry method: Accurately measured aliquots of oxfendazole stock standard solution (1 mg mL$^{-1}$) were spotted onto TLC plate using Camag Linomat auto sampler with micro syringe (100µL). The plate was then developed by the ascending technique using chloroform: methanol: acetic acid (90:8:2, by volume) as a mobile phase. The plate was then removed and air-dried. The chromatogram was scanned at 292 nm. Calibration curve representing the relationship between integrated peak area and the corresponding concentrations of oxfendazole was plotted.

Application to laboratory prepared mixtures

Aliquots of oxfendazole and its degradation product were mixed to prepare different mixtures containing different ratios of both. The procedures mentioned under construction of calibration curves were followed and the concentrations of oxfendazole were calculated.

Application to pharmaceutical formulation

Volume of Unifendazole® suspension (22.5 w/v oxfendazole) equivalent to 250mg oxfendazole was accurately taken and dissolved in 10mL 0.1M methanolic hydrochloric acid in 250mL flask then complete to volume with methanol, shacked, and then filtered to obtain a solution labeled to contain (1mg mL$^{-1}$) of oxfendazole. 10mL of the filtrate were accurately transferred into 100mL volumetric flask then complete to volume with methanol to obtain a solution labeled to contain (100µg mL$^{-1}$) of oxfendazole. The solution was analyzed using the procedures described previously.

Results and discussion

Degradation of oxfendazole

It is found that complete alkaline degradation of oxfendazole was obtained after refluxing the drug with 1M sodium hydroxide at 100°C for 1hr, and the degradation was confirmed by TLC method using chloroform: methanol: acetic acid (90:8:2, by volume) as a developing system, where a suggested degradation pathway is shown as follows:

Identification of the degradation product: Infra red (IR) spectrum of the degradation product showed abroad peak at 3404cm$^{-1}$ which may be assigned to the primary amine group, also disappearance of the peaks at 2741cm$^{-1}$ of the methyl group and at 1724cm$^{-1}$ of the carbonyl group, (Figure 2 & Figure 3). Mass spectrometry showed that the compound has a molar mass of 256.96 indicating the presence of the degradation product, (Figure 4 & Figure 5).

In conclusion, all the above evidences indicate that the degradation product could be 2-amino-5-Phenylsulfinyl benzimidazole, (Scheme 1). The suggested chromatographic system for the HPLC method allows complete base line separation at reasonable time. Planar chromatography with precise application of the samples and computer controlled evaluation and quantification of the developed chromatograms has been considered to be a reliable technique for purity control and for quantitative drug testing.
Chromatographic conditions: Several trials were applied to develop the optimum chromatographic conditions for the sufficient separation of oxfendazole and its degradation product.

HPLC method was applied to separate oxfendazole and its degradation product, therefore several trials have been undertaken to reach the optimum stationary/mobile phases matching. Good chromatographic separation of the two components in their mixtures could be achieved by using BDS Hypersil C18 column (4.6×250mm), particle size (5μm), with a mobile phase consisting of potassium dihydrogen phosphate (pH 5): methanol: acetonitrile (50:30:20, by volume) at flow rate 1.0mL min⁻¹, followed by UV detection at 225nm, (Figure 6). The results of the TLC system were satisfactory when using chloroform: methanol: acetic acid (90:8:2, by volume) as the developing system. Rf values were found to be 0.75 and 0.20 for oxfendazole and its degradation product, respectively as shown in (Figures 7-9). This separation allows the determination of oxfendazole at 292nm without any interference from its degradation product.

Figure 2 IR spectrum of intact oxfendazole on KBr disc.

Figure 3 IR spectrum of oxfendazole degradation product on KBr disc.

Figure 4 Mass spectrum of intact oxfendazole.

Figure 5 Mass spectrum of intact oxfendazole degradation product.

Figure 6 HPLC chromatogram of mixture of intact oxfendazole (10µg mL⁻¹) and its degradation product (10µg mL⁻¹).

Figure 7 TLC- densitometric chromatogram of oxfendazole (0.5-6µg/spot) at 292nm.
Figure 8 3D TLC- densitometric chromatogram of oxfendazole (0.5-5.5µg/spot) and its degradation product (5.5-0.5µg/spot) at 292nm.

Figure 9 2D TLC- densitometric chromatogram of intact oxfendazole (3µg/spot) and its degradation product (3µg/spot) at 292nm.

Scheme 1 Suggested degradation pathway of oxfendazole.

Methods validation: Validations of the proposed methods were assessed as per the ICH guidelines of accuracy, precision, repeatability, interday precision, linearity.

Linearity and range: Calibration graphs were constructed by plotting the area under peak values versus drug concentrations. The regression plot was found to be linear over the range of (3-15µg mL⁻¹) for RP-HPLC method and over the range of (0.5-6µg/spot) for TLC-densitometric method. The linear regression equations for the graphs were:

\[ y = 139699x - 2848.1 \] (\( r^2 = 0.9998 \)), for RP-HPLC method.

\[ y = 1188.4x + 4641.8 \] (\( r^2 = 0.9996 \)), for TLC-densitometric method.

Where \( y \) is the area under peak values, \( x \) is the drug concentration and \( r^2 \) is the determination coefficient. Linearity range, regression equation, intercept, slope and determination coefficient for the calibration data were presented in Table 1.

Limits of detection and quantitation: The limits of detection (LOD) and the limits of quantitation (LOQ) were calculated according to ICH guidelines from the following equations:

\[ \text{LOD} = 3.3\sigma/S \]
\[ \text{LOQ} = 10\sigma/S \]

Where \( \sigma \) is the standard deviation of y-intercepts of regression lines and \( S \) is the slope of the calibration curve. LOD and LOQ values were mentioned in Table 1.

Table 1 Assay validation sheet of the proposed methods

| Parameter                        | RP-HPLC method | TLC-densitometric method |
|----------------------------------|----------------|--------------------------|
| Accuracy (mean±RSD)              | 100.25±0.447   | 100.10±0.385             |
| Precision                        |                |                          |
| Repeatability (RSD)              | 0.3            | 0.48                     |
| Intermediate precision (RSD)     | 0.307          | 0.477                    |
| Wavelength                       | 225nm          | 292nm                    |
| Linearity range                  | (3-15µg mL⁻¹)  | (0.5-6µg/spot)           |
| Slope                            | 139699         | 1188.4                   |
| Intercept                        | -2848.1        | 4641.8                   |
| Coefficient of determination \( r^2 \) | 0.9998         | 0.9996                   |
| LOD                              | 0.144µg mL⁻¹   | 0.093µg/spot             |
| LOQ                              | 0.436µg mL⁻¹   | 0.282µg/spot             |

1Average of three determinations for three concentrations (5,10 and 15µg mL⁻¹ for RP-HPLC method), and (1,3 and 5µg/spot for TLC-densitometric method) of oxfendazole repeated three times.

2The intraday (n=3), average of three concentrations (5,10 and 15µg mL⁻¹ for RP-HPLC method), and (1,3 and 5µg/spot for TLC-densitometric method), of oxfendazole repeated three times within the day.

3The interday (n=3), average of three concentrations (5,10 and 15µg mL⁻¹ for RP-HPLC method), and (1,3 and 5µg/spot for TLC-densitometric method), of oxfendazole repeated three times in three days.

Accuracy: The proposed methods were applied for measuring different concentrations of oxfendazole within their linearity range and the concentrations were calculated each from their corresponding regression equations. The accuracy of the proposed methods was calculated and RSD% was obtained. Good results were obtained as shown in Table 1.

Precision: Precision was evaluated by calculating intraday (repeatability) and interday (Intermediate precision) precision after repeating measuring of the three different concentrations three times in the same day and assaying the sample in triplicate on three successive days using the proposed methods. The calculated RSD % values were listed as shown in Table 1 indicating satisfying precision of the proposed methods.

Specificity: The specificity of the proposed methods was assured by applying them to laboratory prepared mixtures of the intact oxfendazole.
together with its degradation product. The proposed procedures were adopted for the selective determination of intact oxfendazole in presence of up to 80% of its degradation product for RP-HPLC method and up to 91.67% for TLC-densitometric method. The mean percentage recovery ±SD % was shown in Table 2. The validity of the proposed procedures is further assessed by applying the standard addition technique showing no interference from excipients. The results obtained were shown in Table 3. System suitability parameters were calculated for oxfendazole in RP-HPLC method and the results are shown in Table 4.

**Table 2**: Determination of oxfendazole in presence of its alkali-degradation product in their laboratory prepared mixtures by the proposed methods

| Method       | Intact in (µg mL⁻¹) | Degradate in (µg mL⁻¹) | Percent of degradate | Intact found in (µg mL⁻¹) | Recovery % of intact |
|--------------|----------------------|------------------------|----------------------|---------------------------|----------------------|
| RP-HPLC      | 12                   | 3                      | 20%                  | 12.15                     | 101.28               |
|              | 10                   | 5                      | 33.33%               | 10.03                     | 100.32               |
|              | 5                    | 10                     | 66.67%               | 5.04                      | 100.88               |
|              | 3                    | 12                     | 80%                  | 3.05                      | 101.87               |
| Mean ± SD%   |                      |                        |                      |                           | 101.09±0.655         |

| TLC-densitometric | Intact in (µg/spot) | Degradate in (µg/spot) | Percent of degradate | Intact found in (µg/spot) | Recovery % of intact |
|-------------------|---------------------|------------------------|----------------------|---------------------------|----------------------|
| 5.5               | 0.5                 | 8.33%                  | 5.46                 | 99.27                     |
| 5                 | 1                   | 16.67%                 | 4.94                 | 98.77                     |
| 3                 | 3                   | 50%                    | 2.96                 | 98.96                     |
| 1                 | 5                   | 83.33%                 | 0.99                 | 99.14                     |
| 0.5               | 5.5                 | 91.67%                 | 0.49                 | 98.14                     |
| Mean ± SD%        |                     |                        |                      |                           | 98.95 ±0.424         |

**Table 3**: Application of standard addition technique to the analysis of Unifendazole® suspension by applying the proposed methods

| Method       | Pharmaceutical Taken (µg/mL) | Pure added (µg mL⁻¹) | Pure found (µg mL⁻¹) | Recovery % |
|--------------|-----------------------------|----------------------|----------------------|------------|
| RP-HPLC      | 5                           | 3                    | 2.99                 | 99.76      |
|              | 5                           | 4.98                 | 99.65                |
|              | 7                           | 7.01                 | 100.13               |
|              | 10                          | 10.03                | 100.35               |
| Mean±SD%     |                             |                      |                      | 99.97±0.326|
| TLC-densitometric | 2                         | 1                    | 0.98                 | 98.65      |
|              | 2                           | 1.96                 | 98.38                |
|              | 3                           | 2.97                 | 99.19                |
|              | 4                           | 3.97                 | 99.24                |
| Mean±SD%     |                             |                      |                      | 98.86±0.417|

**Table 4**: Parameters of the system suitability test of the HPLC method

| Parameter       | Oxfendazole | Reference values²¹ |
|-----------------|-------------|--------------------|
| Resolution (R)  | 6.5         | R > 1.5            |
| Selectivity factor (α) | 2.66 | > 1 |
| Retention time (tR) | 7.3 min | |
| Capacity factor (K') | 2.47 | 1–10 |
| Theoretical plates (N) | 2370 | |
| Tailing factor (T) | 1.15 | T=1 for a typical symmetric peak |

Citation: Salama FM, Attia KAM, Mohamad AA, et al. RP-HPLC and TLC-densitometric methods for determination of oxfendazole in the presence of its alkali-induced degradation product. *J Anal Pharm Res*. 2018;7(2):140–145. DOI: 10.15406/japlr.2018.07.00214
Statistical analysis

In order to compare the ability of the proposed methods for the determination of oxendazole in pharmaceutical preparation, the results obtained by applying each of the proposed methods and the reported spectrophotometric method were subjected to statistical analysis Table 5. The calculated t and F values were less than the theoretical ones indicating that there were no significant differences between the proposed and the reported methods.

Table 5 Statistical comparison for the results obtained by the proposed methods and the reported method for the analysis of oxendazole in Unifenazole® (22.5% w/v) suspension.

| Method          | RP-HPLC | TLC-densitometric | Reported method |
|-----------------|---------|-------------------|-----------------|
| n*              | 5       | 5                 | 5               |
| $\chi^2$        | 99.83   | 99.48             | 99.83           |
| SD              | 0.746   | 0.653             | 0.478           |
| RSD%            | 0.747   | 0.656             | 0.479           |
| t**             | 0.060(2,306) | 1.021(2,306)   |                |
| F**             | 2.427(6,388) | 1.846(6,388)   |                |

*No. of experiment
**The values in the parenthesis are tabulated values of t and F at $p=0.05$ level of significance

Conclusion

In this work, two chromatographic methods were developed and applied for the determination of oxendazole in the presence of its alkali-induced degradation product. The advantage of the TLC-densitometric method is that several samples can be run simultaneously using a small quantity of the mobile phase, thus lowering the analysis time and cost per analysis, as well as providing high sensitivity and selectivity. The proposed methods were successfully applied to Unifenazole® suspension and no interference from pharmaceutical formulation excipients was found.

Acknowledgements

I am deeply thankful to ALLAH, by the grace of whom this work was realized. I wish to express my indebtedness and gratitude to staff members Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy Al-Azhar University, Cairo, Egypt for their valuable supervision, continuous guidance, and encouragement throughout the whole work.

Conflict of interest

The author declares there is no conflict of interest

References

1. Windholz M. The Merck Index: an encyclopedia of Chemicals. NJ: Drugs and biological. Merck & co., Inc., Rahway; 1983.
2. Reynolds JEF. Martindale, The Extra Pharmacopoeia. London: The Royal Pharmaceutical Society; 1993.
3. United States Pharmacopoeia. 34th ed. National formulary 29. Official monographs. 2011.
4. Rajendraprasad N, Basavaiah K. Potentiometric determination of piroxicam and oxendazole in pharmaceuticals. Current Chemistry Letters. 2016;5(1):33–46.
5. Nerenberg C, Runkel RA, Matin SB. Radioimmunoassay of oxendazole in bovine, equine, or canine plasma or serum. J Pharm Sci. 1978;67(11):1553–1557.
6. Rajendraprasad N, Basavaiah K. UV/Visible Spectroscopic Quantification Of Veterinary Anthelmintic Drug Oxendazole In Pharmaceuticals. J Applied Spectro. 2016;83(3):392–397.
7. Tsina IW, Matin SB. Determination of Oxendazole in Cow Milk by Reversed Phase HighPerformance Liquid Chromatography. J Pharm Sci. 1981;70(8):858–860.
8. Su SC, Chou HH, Chang PC, et al. Simultaneous Determination of Febantel, Fenbendazole, Oxendazole and Oxendazole Sulfone in Livestock by Matrix Solid Phase Dispersion Extraction Technique and HPLC. J Food and Drug Analysis. 2004;12(3):244–253.
9. Blanchflower WJ, Cannavan A, Kennedy DG. Determination of fenbantel and oxendazole in liver and muscle using liquid chromatography mass spectrometry. Analyst. 1994;119(6):1325–1328.
10. Shah G, Bradley D, Shek E. Liquid chromatographic determination of oxendazole in swine feeds. J Assoc Off Anl Chem. 1984;67(4):707–714.
11. Fleetman J, Neu D, Benjamin E. Analysis of pharmaceutical dosage forms for oxendazole: II. Simultaneous liquid chromatographic determination of oxendazole and trichlorfon in equine paste. J Assoc Off Anl Chem. 1986;69(1):24–28.
12. Khan AR, Akhtar MJ, Mahmood R, et al. LC assay method for oxendazole and oxyclozanide in pharmaceutical preparation. Journal of Pharm and Biomedical Anal. 2000;22(1):111–114.
13. Kulik A, Bialecka W, Podolska M, et al. HPLC Method For Identification And Quantification Of Benzimidazole Derivatives In Antiparasitic Drugs. Acta Pol Pharm. 2011;68(6):823–829.
14. Tai SS, Cargile N, Barnes CJ. Determination of thiabendazole, 5 hydroxy thiabendazole, fenbendazole, and oxendazole in milk. J Assoc Off Anl Chem. 1990;73(3):368–373.
15. Havlíková L, Brabcová I, Satinský D, et al. Optimisation of an HPLC method for the simultaneous determination of pyrantel pamoate, praziquantel, fenbendazole, oxendazole and buthydryoxyanisolase using a phenyl stationary phase. Anal methods. 2012;4(6):1592–1597.
16. Nakos DS, Botsoglou NA, Psomas IE. Ion– Pair Isolation and Liquid Chromatographic Dnimeration of Albendazole, Oxendazole, Oxendazole and Thiabendazole Residues in Milk. J Liquid Chromatography. 1994;17(19):4145–4155.
17. Klaus G, Keller E, Sára Z, et al. Simultaneous determination of praziquantel, pyrantel embonate, febantel and its active metabolites, oxendazole and fenbendazole, in dog plasma by liquid chromatography mass spectrometry. Biomed Chromatogr. 2015;29(12):1859–1865.
18. Malviya R, Bansal V, Pal OP, et al. High performance liquid chromatography: a short review. J Global Pharm Technol. 2010;(5):22–26.
19. Renger B, editors. In Proceedings of the sixth international symposium on Instrumental planar chromatography. Bad Duerkheim, Germany; 1991.
20. Validation of Analytical Procedures. Proceedings of International Conference on Harmonization, World Health Organization. Geneva, Switzerland. 2015.
21. Adamovics IA. Chromatographic Analysis of Pharmaceuticals. New York. 1997.

Citation: Salama FM, Attia KAM, Mohamad AA, et al. RP- HPLC and TLC- densitometric methods for determination of oxendazole in the presence of its alkali-induced degradation product. J Anal Pharm Res. 2018;7(2):140–145. DOI: 10.15406/japlr.2018.07.00214